Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 727 entries
Sorted by: Best Match Show Resources per page
Effect of NaCl on the Lifetime of Micro- and Nanobubbles.

Nanomaterials (Basel, Switzerland)

Uchida T, Liu S, Enari M, Oshita S, Yamazaki K, Gohara K.
PMID: 28344288
Nanomaterials (Basel). 2016 Feb 05;6(2). doi: 10.3390/nano6020031.

Micro- and nanobubbles (MNBs) are potentially useful for industrial applications such as the purification of wastewater and the promotion of physiological activities of living organisms. To develop such applications, we should understand their properties and behavior, such as their...

Cite
Uchida T, Liu S, Enari M, et al. Effect of NaCl on the Lifetime of Micro- and Nanobubbles. Nanomaterials (Basel). 2016;6(2)doi: 10.3390/nano6020031.
Uchida, T., Liu, S., Enari, M., Oshita, S., Yamazaki, K., & Gohara, K. (2016). Effect of NaCl on the Lifetime of Micro- and Nanobubbles. Nanomaterials (Basel, Switzerland), 6(2), . https://doi.org/10.3390/nano6020031
Uchida, Tsutomu, et al. "Effect of NaCl on the Lifetime of Micro- and Nanobubbles." Nanomaterials (Basel, Switzerland) vol. 6,2 (2016). doi: https://doi.org/10.3390/nano6020031
Uchida T, Liu S, Enari M, Oshita S, Yamazaki K, Gohara K. Effect of NaCl on the Lifetime of Micro- and Nanobubbles. Nanomaterials (Basel). 2016 Feb 05;6(2). doi: 10.3390/nano6020031. PMID: 28344288; PMCID: PMC5302484.
Copy Download .nbib Format: NLM
Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients.

Case reports in oncology

Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H.
PMID: 28512412
Case Rep Oncol. 2017 Apr 04;10(1):290-295. doi: 10.1159/000461576. eCollection 2017.

Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be...

Cite
Imafuku K, Yoshino K, Yamaguchi K, et al. Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case Rep Oncol. 2017;10(1):290-295doi: 10.1159/000461576.
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case reports in oncology, 10(1), 290-295. https://doi.org/10.1159/000461576
Imafuku, Keisuke, et al. "Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients." Case reports in oncology vol. 10,1 (2017): 290-295. doi: https://doi.org/10.1159/000461576
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case Rep Oncol. 2017 Apr 04;10(1):290-295. doi: 10.1159/000461576. eCollection 2017. PMID: 28512412; PMCID: PMC5422723.
Copy Download .nbib Format: NLM
Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events.

Case reports in oncology

Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H.
PMID: 28512413
Case Rep Oncol. 2017 Apr 04;10(1):296-300. doi: 10.1159/000463379. eCollection 2017.

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, it is...

Cite
Imafuku K, Yoshino K, Yamaguchi K, et al. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol. 2017;10(1):296-300doi: 10.1159/000463379.
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case reports in oncology, 10(1), 296-300. https://doi.org/10.1159/000463379
Imafuku, Keisuke, et al. "Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events." Case reports in oncology vol. 10,1 (2017): 296-300. doi: https://doi.org/10.1159/000463379
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol. 2017 Apr 04;10(1):296-300. doi: 10.1159/000463379. eCollection 2017. PMID: 28512413; PMCID: PMC5422733.
Copy Download .nbib Format: NLM
A Novel Combinatorial Therapy With Pulp Stem Cells and Granulocyte Colony-Stimulating Factor for Total Pulp Regeneration.

Stem cells translational medicine

Iohara K, Murakami M, Takeuchi N, Osako Y, Ito M, Ishizaka R, Utunomiya S, Nakamura H, Matsushita K, Nakashima M.
PMID: 28945010
Stem Cells Transl Med. 2013 Oct;2(10):818. doi: 10.5966/sctm.2012-0132erratum.

No abstract available.

Cite
Iohara K, Murakami M, Takeuchi N, et al. A Novel Combinatorial Therapy With Pulp Stem Cells and Granulocyte Colony-Stimulating Factor for Total Pulp Regeneration. Stem Cells Transl Med. 2013;2(10):818doi: 10.5966/sctm.2012-0132erratum.
Iohara, K., Murakami, M., Takeuchi, N., Osako, Y., Ito, M., Ishizaka, R., Utunomiya, S., Nakamura, H., Matsushita, K., & Nakashima, M. (2013). A Novel Combinatorial Therapy With Pulp Stem Cells and Granulocyte Colony-Stimulating Factor for Total Pulp Regeneration. Stem cells translational medicine, 2(10), 818. https://doi.org/10.5966/sctm.2012-0132erratum
Iohara, Koichiro, et al. "A Novel Combinatorial Therapy With Pulp Stem Cells and Granulocyte Colony-Stimulating Factor for Total Pulp Regeneration." Stem cells translational medicine vol. 2,10 (2013): 818. doi: https://doi.org/10.5966/sctm.2012-0132erratum
Iohara K, Murakami M, Takeuchi N, Osako Y, Ito M, Ishizaka R, Utunomiya S, Nakamura H, Matsushita K, Nakashima M. A Novel Combinatorial Therapy With Pulp Stem Cells and Granulocyte Colony-Stimulating Factor for Total Pulp Regeneration. Stem Cells Transl Med. 2013 Oct;2(10):818. doi: 10.5966/sctm.2012-0132erratum. PMID: 28945010; PMCID: PMC3785266.
Copy Download .nbib Format: NLM
Temporal lobe epilepsy associated with GAD autoimmunity.

Acta diabetologica

Obata A, Kutoku Y, Sunada Y, Okauchi S, Kimura T, Hirukawa H, Tanabe A, Kinoshita T, Kohara K, Tatsumi F, Shimoda M, Kamei S, Nakanishi S, Mune T, Kaku K, Kaneto H.
PMID: 27638303
Acta Diabetol. 2017 Mar;54(3):321-323. doi: 10.1007/s00592-016-0910-9. Epub 2016 Sep 08.

No abstract available.

Cite
Obata A, Kutoku Y, Sunada Y, et al. Temporal lobe epilepsy associated with GAD autoimmunity. Acta Diabetol. 2016;54(3):321-323doi: 10.1007/s00592-016-0910-9.
Obata, A., Kutoku, Y., Sunada, Y., Okauchi, S., Kimura, T., Hirukawa, H., Tanabe, A., Kinoshita, T., Kohara, K., Tatsumi, F., Shimoda, M., Kamei, S., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2017). Temporal lobe epilepsy associated with GAD autoimmunity. Acta diabetologica, 54(3), 321-323. https://doi.org/10.1007/s00592-016-0910-9
Obata, Atsushi, et al. "Temporal lobe epilepsy associated with GAD autoimmunity." Acta diabetologica vol. 54,3 (2017): 321-323. doi: https://doi.org/10.1007/s00592-016-0910-9
Obata A, Kutoku Y, Sunada Y, Okauchi S, Kimura T, Hirukawa H, Tanabe A, Kinoshita T, Kohara K, Tatsumi F, Shimoda M, Kamei S, Nakanishi S, Mune T, Kaku K, Kaneto H. Temporal lobe epilepsy associated with GAD autoimmunity. Acta Diabetol. 2017 Mar;54(3):321-323. doi: 10.1007/s00592-016-0910-9. Epub 2016 Sep 08. PMID: 27638303; PMCID: PMC5329084.
Copy Download .nbib Format: NLM
Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers.

Clinical pharmacology : advances and applications

Kawabata M, Yokoyama Y, Sasaki T, Tao S, Ihara K, Shirai Y, Sasano T, Goya M, Furukawa T, Isobe M, Hirao K.
PMID: 25733934
Clin Pharmacol. 2015 Feb 16;7:29-36. doi: 10.2147/CPAA.S77021. eCollection 2015.

PURPOSE: Drug-induced bradycardia is common during antiarrhythmic therapy; the major culprits are beta-blockers. However, whether other antiarrhythmic drugs are also a significant cause of this, alone or in combination with beta-blockers, is not well known.METHODS: We retrospectively investigated the...

Cite
Kawabata M, Yokoyama Y, Sasaki T, et al. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015;7:29-36doi: 10.2147/CPAA.S77021.
Kawabata, M., Yokoyama, Y., Sasaki, T., Tao, S., Ihara, K., Shirai, Y., Sasano, T., Goya, M., Furukawa, T., Isobe, M., & Hirao, K. (2015). Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clinical pharmacology : advances and applications, 729-36. https://doi.org/10.2147/CPAA.S77021
Kawabata, Mihoko, et al. "Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers." Clinical pharmacology : advances and applications vol. 7 (2015): 29-36. doi: https://doi.org/10.2147/CPAA.S77021
Kawabata M, Yokoyama Y, Sasaki T, Tao S, Ihara K, Shirai Y, Sasano T, Goya M, Furukawa T, Isobe M, Hirao K. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015 Feb 16;7:29-36. doi: 10.2147/CPAA.S77021. eCollection 2015. PMID: 25733934; PMCID: PMC4337503.
Copy Download .nbib Format: NLM
A top-down methodology for ultrafast tuning of nanosized zeolites.

Chemical communications (Cambridge, England)

Liu Z, Nomura N, Nishioka D, Hotta Y, Matsuo T, Oshima K, Yanaba Y, Yoshikawa T, Ohara K, Kohara S, Takewaki T, Okubo T, Wakihara T.
PMID: 26154841
Chem Commun (Camb). 2015 Aug 14;51(63):12567-70. doi: 10.1039/c5cc04542h.

We herein present a top-down methodology to prepare nanosized zeolites with tunable size by combining post-synthesis milling and fast recrystallization of several minutes (10 min for SSZ-13 and 5 min for AlPO4-5). A continuous-flow recrystallization process is demonstrated to...

Cite
Liu Z, Nomura N, Nishioka D, et al. A top-down methodology for ultrafast tuning of nanosized zeolites. Chem Commun (Camb). 2015;51(63):12567-70doi: 10.1039/c5cc04542h.
Liu, Z., Nomura, N., Nishioka, D., Hotta, Y., Matsuo, T., Oshima, K., Yanaba, Y., Yoshikawa, T., Ohara, K., Kohara, S., Takewaki, T., Okubo, T., & Wakihara, T. (2015). A top-down methodology for ultrafast tuning of nanosized zeolites. Chemical communications (Cambridge, England), 51(63), 12567-70. https://doi.org/10.1039/c5cc04542h
Liu, Zhendong, et al. "A top-down methodology for ultrafast tuning of nanosized zeolites." Chemical communications (Cambridge, England) vol. 51,63 (2015): 12567-70. doi: https://doi.org/10.1039/c5cc04542h
Liu Z, Nomura N, Nishioka D, Hotta Y, Matsuo T, Oshima K, Yanaba Y, Yoshikawa T, Ohara K, Kohara S, Takewaki T, Okubo T, Wakihara T. A top-down methodology for ultrafast tuning of nanosized zeolites. Chem Commun (Camb). 2015 Aug 14;51(63):12567-70. doi: 10.1039/c5cc04542h. PMID: 26154841.
Copy Download .nbib Format: NLM
Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy.

Heart Asia

Iwase T, Takao S, Akaike M, Adachi K, Sumitomo-Ueda Y, Yagi S, Niki T, Kusunose K, Tomita N, Hirata Y, Yamaguchi K, Koshiba K, Taketani Y, Yamada H, Soeki T, Wakatsuki T, Aihara K, Harada M, Nishitani H, Sata M.
PMID: 27325943
Heart Asia. 2010 Jul 29;2(1):52-5. doi: 10.1136/ha.2010.002006. eCollection 2010.

BACKGROUND: Cardiac involvement is a recognised complication in female carriers of Duchenne muscular dystrophy (DMD). Since segmental or global left ventricle (LV) wall motion abnormalities in DMD carriers can arise even without apparent muscle weakness, it is difficult to...

Cite
Iwase T, Takao S, Akaike M, et al. Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy. Heart Asia. 2010;2(1):52-5doi: 10.1136/ha.2010.002006.
Iwase, T., Takao, S., Akaike, M., Adachi, K., Sumitomo-Ueda, Y., Yagi, S., Niki, T., Kusunose, K., Tomita, N., Hirata, Y., Yamaguchi, K., Koshiba, K., Taketani, Y., Yamada, H., Soeki, T., Wakatsuki, T., Aihara, K., Harada, M., Nishitani, H., & Sata, M. (2010). Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy. Heart Asia, 2(1), 52-5. https://doi.org/10.1136/ha.2010.002006
Iwase, Takashi, et al. "Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy." Heart Asia vol. 2,1 (2010): 52-5. doi: https://doi.org/10.1136/ha.2010.002006
Iwase T, Takao S, Akaike M, Adachi K, Sumitomo-Ueda Y, Yagi S, Niki T, Kusunose K, Tomita N, Hirata Y, Yamaguchi K, Koshiba K, Taketani Y, Yamada H, Soeki T, Wakatsuki T, Aihara K, Harada M, Nishitani H, Sata M. Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy. Heart Asia. 2010 Jul 29;2(1):52-5. doi: 10.1136/ha.2010.002006. eCollection 2010. PMID: 27325943; PMCID: PMC4898527.
Copy Download .nbib Format: NLM
Homogeneous Photocatalytic Water Oxidation with a Dinuclear Co(III)-Pyridylmethylamine Complex.

Inorganic chemistry

Ishizuka T, Watanabe A, Kotani H, Hong D, Satonaka K, Wada T, Shiota Y, Yoshizawa K, Ohara K, Yamaguchi K, Kato S, Fukuzumi S, Kojima T.
PMID: 26810593
Inorg Chem. 2016 Feb 01;55(3):1154-64. doi: 10.1021/acs.inorgchem.5b02336. Epub 2016 Jan 21.

A bis-hydroxo-bridged dinuclear Co(III)-pyridylmethylamine complex (1) was synthesized and the crystal structure was determined by X-ray crystallography. Complex 1 acts as a homogeneous catalyst for visible-light-driven water oxidation by persulfate (S2O8(2-)) as an oxidant with [Ru(II)(bpy)3](2+) (bpy = 2,2'-bipyridine)...

Cite
Ishizuka T, Watanabe A, Kotani H, et al. Homogeneous Photocatalytic Water Oxidation with a Dinuclear Co(III)-Pyridylmethylamine Complex. Inorg Chem. 2016;55(3):1154-64doi: 10.1021/acs.inorgchem.5b02336.
Ishizuka, T., Watanabe, A., Kotani, H., Hong, D., Satonaka, K., Wada, T., Shiota, Y., Yoshizawa, K., Ohara, K., Yamaguchi, K., Kato, S., Fukuzumi, S., & Kojima, T. (2016). Homogeneous Photocatalytic Water Oxidation with a Dinuclear Co(III)-Pyridylmethylamine Complex. Inorganic chemistry, 55(3), 1154-64. https://doi.org/10.1021/acs.inorgchem.5b02336
Ishizuka, Tomoya, et al. "Homogeneous Photocatalytic Water Oxidation with a Dinuclear Co(III)-Pyridylmethylamine Complex." Inorganic chemistry vol. 55,3 (2016): 1154-64. doi: https://doi.org/10.1021/acs.inorgchem.5b02336
Ishizuka T, Watanabe A, Kotani H, Hong D, Satonaka K, Wada T, Shiota Y, Yoshizawa K, Ohara K, Yamaguchi K, Kato S, Fukuzumi S, Kojima T. Homogeneous Photocatalytic Water Oxidation with a Dinuclear Co(III)-Pyridylmethylamine Complex. Inorg Chem. 2016 Feb 01;55(3):1154-64. doi: 10.1021/acs.inorgchem.5b02336. Epub 2016 Jan 21. PMID: 26810593.
Copy Download .nbib Format: NLM
A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy.

Clinical journal of gastroenterology

Miura H, Ijichi M, Ando Y, Hayama K, IIhara K, Yamada H, Bandai Y.
PMID: 26182139
Clin J Gastroenterol. 2013 Dec;6(6):470-5. doi: 10.1007/s12328-013-0421-y. Epub 2013 Sep 12.

Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) usually occurs in patients with metabolic syndrome. However, it can develop in relation with pancreaticoduodenectomy (PD) independent of insulin resistance. NAFLD/NASH potentially progresses to liver cirrhosis and subsequent end-stage liver disease, but...

Cite
Miura H, Ijichi M, Ando Y, et al. A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy. Clin J Gastroenterol. 2013;6(6):470-5doi: 10.1007/s12328-013-0421-y.
Miura, H., Ijichi, M., Ando, Y., Hayama, K., IIhara, K., Yamada, H., & Bandai, Y. (2013). A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy. Clinical journal of gastroenterology, 6(6), 470-5. https://doi.org/10.1007/s12328-013-0421-y
Miura, Hideaki, et al. "A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy." Clinical journal of gastroenterology vol. 6,6 (2013): 470-5. doi: https://doi.org/10.1007/s12328-013-0421-y
Miura H, Ijichi M, Ando Y, Hayama K, IIhara K, Yamada H, Bandai Y. A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy. Clin J Gastroenterol. 2013 Dec;6(6):470-5. doi: 10.1007/s12328-013-0421-y. Epub 2013 Sep 12. PMID: 26182139.
Copy Download .nbib Format: NLM
Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.

Oncology letters

Komeno Y, Uchida N, Satoh Y, Uryu H, Iwata Y, Masuda A, Iihara K, Yatomi Y, Taniguchi S, Ryu T.
PMID: 28599428
Oncol Lett. 2017 Jun;13(6):4285-4289. doi: 10.3892/ol.2017.5989. Epub 2017 Apr 05.

A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase....

Cite
Komeno Y, Uchida N, Satoh Y, et al. Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncol Lett. 2017;13(6):4285-4289doi: 10.3892/ol.2017.5989.
Komeno, Y., Uchida, N., Satoh, Y., Uryu, H., Iwata, Y., Masuda, A., Iihara, K., Yatomi, Y., Taniguchi, S., & Ryu, T. (2017). Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncology letters, 13(6), 4285-4289. https://doi.org/10.3892/ol.2017.5989
Komeno, Yukiko, et al. "Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report." Oncology letters vol. 13,6 (2017): 4285-4289. doi: https://doi.org/10.3892/ol.2017.5989
Komeno Y, Uchida N, Satoh Y, Uryu H, Iwata Y, Masuda A, Iihara K, Yatomi Y, Taniguchi S, Ryu T. Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncol Lett. 2017 Jun;13(6):4285-4289. doi: 10.3892/ol.2017.5989. Epub 2017 Apr 05. PMID: 28599428; PMCID: PMC5452986.
Copy Download .nbib Format: NLM
Adamantane-based Bidendate Metal Complexes in Crystalline and Solution State.

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry

Ohara K, Tominaga M, Masu H, Azumaya I, Yamaguchi K.
PMID: 27941266
Anal Sci. 2016;32(12):1347-1352. doi: 10.2116/analsci.32.1347.

Bidentate organic molecules with imidazole or benzimidazole moieties connected to a rigid 1,3-diphenyladamantane spacer are simple and unique building blocks that facilitate the assembly of supramolecular architectures in the solid state via metal-coordination. Single-crystal X-ray analysis revealed that the...

Cite
Ohara K, Tominaga M, Masu H, et al. Adamantane-based Bidendate Metal Complexes in Crystalline and Solution State. Anal Sci. 2016;32(12):1347-1352doi: 10.2116/analsci.32.1347.
Ohara, K., Tominaga, M., Masu, H., Azumaya, I., & Yamaguchi, K. (2016). Adamantane-based Bidendate Metal Complexes in Crystalline and Solution State. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 32(12), 1347-1352. https://doi.org/10.2116/analsci.32.1347
Ohara, Kazuaki, et al. "Adamantane-based Bidendate Metal Complexes in Crystalline and Solution State." Analytical sciences : the international journal of the Japan Society for Analytical Chemistry vol. 32,12 (2016): 1347-1352. doi: https://doi.org/10.2116/analsci.32.1347
Ohara K, Tominaga M, Masu H, Azumaya I, Yamaguchi K. Adamantane-based Bidendate Metal Complexes in Crystalline and Solution State. Anal Sci. 2016;32(12):1347-1352. doi: 10.2116/analsci.32.1347. PMID: 27941266.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 727 entries